Lipella Pharmaceuticals
LIPO

$0.4250

8.92%

Market Cap: $3.44M

About: Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $260K [Q1] → $284K (+$24K) [Q2]

2.21% more ownership

Funds ownership: 6.08% [Q1] → 8.28% (+2.21%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

22% less funds holding

Funds holding: 9 [Q1] → 7 (-2) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for LIPO.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about LIPO published over the past 30 days

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C.

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases 5 th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024. LP-20, which has completed preclinical and proof-of-concept human trials, is administered via catheter into the bladder.

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

PITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella's Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic Oral Lichen Planus, a chronic inflammatory condition that affects mucous membranes in the mouth and causes burning and pain as well as white patches, swollen tissue or open sores.

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?

Lipella Pharmaceuticals (NASDAQ: LIPO ) stock is flying higher on Monday after the company presented investors with an update on its Phase 2a clinical trial evaluating LP-310. This is the company's drug candidate for the treatment of Oral Lichen Planus ( OLP ).

Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?

See News Rankings